Pepscan appoints chief business officer

Michiel Lodder joins the Dutch firm from OctoPlus

Pepscan Therapeutics, a Dutch biotech company focused on protein mimicry for the discovery of therapeutics peptides and antibodies, has appointed Michiel Lodder as chief business officer.

Lodder joins the firm from OctoPlus, where he was senior manager business development, responsible for licensing, partnering, and alliance management activities.

Pepscan has recently established a number of research collaboration and licensing agreements with major pharma and biotech companies, and Lodder’s experience is expected to enable the firm to add to these partnerships.

You may also like

Research & Development

Pepscan Therapeutics signs agreement with Crucell

Partners aim to develop of novel vaccines to combat infectious diseases
Research & Development

Pepscan agrees research collaboration with Tibotec

Will use CLIPS to develop therapeutic peptides
Research & Development

Immunovo secures seed funding from venture capitalists

Signs partnering agreement with Pepscan, which takes minority interest in Immunovo
Manufacturing

Anxine responds to rising demand for integrated turnkey packaging solutions

Anxine has observed that more customers are moving away from purchasing individual machines and are instead choosing complete one-stop turnkey solutions that are easier to plan, manage, and put into operation
Pharmaceutical

MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients

The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
Regulatory

How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing

As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Subscribe now